PA-SYNERGIS-SOFTWARE
11.1.2022 15:02:09 CET | Business Wire | Press release
Synergis Software , a global leader in document management and workflow solutions, today announced that its flagship product, Adept, has earned 30 #1 rankings in G2’s Winter 2022 Grid Reports. The first-place rankings extend across G2’s Enterprise Content Management, Product Data Management, and Construction Drawing Management categories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111005239/en/
The G2 reports, based on independently validated reviews, highlight key advantages that matter most to customers, including “best usability”, “easiest setup”, “fastest implementation”, “best support”, and “best relationship”.
Adept retains its position at the very top of G2’s Implementation Index, Usability Index, and Relationship Index for Product Data Management (PDM) for the sixth consecutive quarter.
“As a software developer and a trusted partner, we take G2’s reports to heart. Understanding how our customers experience our software and the partnership they have with us is a critical guidepost for our business”, said Scott Lamond, vice president of marketing at Synergis Software. “Our customers’ voices enliven our product direction and reflect how well we’re serving them.”
The Winter 2022 Grid® Reports are based on G2’s unique algorithm, which calculates customer satisfaction and market presence scores in real-time. Results from user reviews and data aggregated from online sources and social networks, Adept earned #1 placements in the following categories:
Product Data Management (PDM)
#1 Usability Index
#1 Implementation Index
#1 Relationship Index
#1 Best Meets Requirements, Mid-Market
#1 Implementation Time
#1 Implementation Time, Mid-Market
#1 Ease of Setup, Mid-Market
#1 Ease of Admin
#1 Ease of Admin, Mid-Market
#1 Ease of Doing Business With, Mid-Market
#1 Most Likely to Recommend
#1 Most Likely to Recommend, Mid-Market
#1 Net Promoter Score
#1 Net Promoter Score, Mid-Market
#1 Quality of Support
#1 Quality of Support, Mid-Market
#1 User Adoption, Mid-Market
#1 in Version Control
Construction Drawing Management
#1 Document Management Features, Small Business
#1 Ease of Doing Business With
#1 Ease of Doing Business With, Small Business
#1 Ease of Setup, Mid-Market
#1 Best Meets Requirements, Small Business
#1 Net Promoter Score
#1 Net Promoter Score, Small Business
#1 Quality of Support
#1 Quality of Support, Mid-Market
#1 Quality of Support, Small Business
Enterprise Content Management (ECM)
#1 Ease of Doing Business With, Mid-Market
#1 Most Likely to Recommend, Mid-Market
Adept also ranks in the top three in Enterprise Content Management for Search, Metadata, Version Control, Likelihood to Recommend, Net Promoter Score, and Relationship Index, Mid-Market.
Synergis was awarded the additional, “Users Love Us” badge, which honors software solutions that are consistently reviewed and highly rated by their users.
Review Feedback from Verified Users on G2 Crowd
Here are some of the quotes from Synergis’ customers in verified reviews on G2:
- “Data is the cornerstone of any business today and not securing it is a huge risk. If you want to do it right and do it well, the Adept platform is the gold-standard."
Ryan Mongeau, Director of Technology
Space Age Electronics
- “I've been in IT for 25 years. I've chatted with thousands of vendors, worked with hundreds of consultants, administered dozens of enterprise software platforms, and the gang at Synergis is my favorite by far. I always—seriously, always —feel like a priority!”
Blake Donley, Sr. IT Analyst
Great River Energy
- "We use Adept to organize construction documents for almost 200 buildings, 6 campuses and nearly 1 billion dollars in active construction. Using Adept, our maintenance technicians and project teams can quickly locate and share the information they need to be successful.”
Chad Thome, Sr IT Business Analyst
University of Houston
- "We manage entire plant documentation for a process plant running 24/7/365. Adept gives us access to current plant conditions, vendor documentation, installation and operating manuals—all available by searching the equipment tag number."
Paul Opiela, Document Control Coordinator
Aux Sable
Read more about Synergis Adept in G2 Winter 2022 Grid Reports here .
Learn how Adept stacks up to the competition in the PDM market here .
About Synergis Software
Synergis Software is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. Adept serves more than 120,000 users across dozens of industries providing fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator connects your enterprise applications so your data and business processes flow seamlessly across your entire IT infrastructure.
Named the customer service leader in the global engineering information management market by Frost & Sullivan and ranked in the Top 5 globally by Helpdesk International for three consecutive years, our commitment to clients is unwavering.
Founded in 1985, Synergis Technologies, LLC is headquartered in Bucks County, PA and is privately owned and funded. For more information, visit SynergisSoftware.com.
Adept has been battle tested by engineers for over 30 years with customers such as Dow Chemical, Con Edison, General Mills, Merck, NASA, and Nucor Steel.
About G2 Crowd
G2 is the world’s largest tech marketplace where businesses can discover, review, and manage the technology they need to reach their potential. Today, more than 3M people visit G2 to read and write authentic reviews about thousands of software products and professional services. G2 has published over 1,000,000 reviews and over 5 million visitors are helping millions of businesses make better buying decisions — and reach their full potential.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005239/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom